Back to results
US 2015/0148247 A1Published application
Methods and devices for tuberculosis diagnosis using biomarker profiles
AssigneesThe Broad Institute, Inc., The General Hospital Corporati d/b/a Massachusetts General Hospital
InventorsRushdy Ahmad, Michael Gillette, Steven A. Carr
Life of this patent
Estimating the term…
Abstract
The invention relates to tuberculosis diagnostic methods and devices that measure particular biomarker profiles in subjects and identify a subject having tuberculosis based on such profiles.
Claims23
A method comprising:
- (a) measuring protein levels of three or more biomarkers in a biological sample from a subject, wherein the biomarkers are selected from
- (i) a first group consisting of AAT, Fibrinogen, Haptoglobin, C3, beta-2-macroglobulin, CRP, ICAM-1, TIMP-1, TNFR2, IL-18, IL-1RA, IL-6, IL-8, TNF-alpha, and VEGF (“Group I biomarker”);
- and/or
- (ii) a second group consisting of A2Macro, MMP-2, VCAM-1, IL-17, and SCF (“Group II biomarker”);
- (b) comparing the Group I and/or Group II biomarker protein levels with control levels;
- and
- (c) identifying a subject with tuberculosis based on
- (i) Group I biomarker protein levels that are elevated in the biological sample compared to the control levels and/or
- (ii) Group II biomarker protein levels that are reduced in the biological sample compared to the control levels.
6 more elements
A method comprising:
- (a) measuring protein levels of three or more biomarkers in a biological sample from a subject, wherein the biomarkers are selected from
- (i) a first group consisting of AAT, Fibrinogen, Haptoglobin, C3, beta-2-macroglobulin, CRP, ICAM-1, TIMP-1, TNFR2, IL-18, IL-1RA, IL-6, IL-8, TNF-alpha, and VEGF (“Group I biomarker”);
- and/or
- (ii) a second group consisting of A2Macro, MMP-2, VCAM-1, IL-17, and SCF (“Group II biomarker”);
- (b) identifying a subject with tuberculosis based on
- (i) a Group I biomarker protein level that is above a pre-determined threshold, and/or
- (ii) a Group II biomarker protein level that is below a pre-determined threshold.
4 more elements
(canceled)
A method comprising:
- (a) measuring protein levels of three or more biomarkers in a biological sample from a subject, wherein the biomarkers are selected from the group consisting of
- (i) a first group consisting of AAT, Fibrinogen, Haptoglobin, C3, beta-2-macroglobulin, CRP, ICAM-1, TIMP-1, TNFR2, IL-18, IL-1RA, IL-6, IL-8, TNF-alpha, and VEGF (“Group I biomarker”);
- and/or
- (ii) a second group consisting of A2Macro, MMP-2, VCAM-1, IL-17, and SCF (“Group II biomarker”);
- and
- (b) identifying a subject with tuberculosis based on
- (i) a Group I biomarker protein level that is above a pre-determined threshold, and/or
- (ii) a Group II biomarker protein level that is below a pre-determined threshold, wherein the predetermined thresholds are set to yield a specificity greater than 50% and/or a sensitivity greater than 50%.
5 more elements
21-24. (canceled)
A device comprising
- a sample inlet and
- binding partners for three or more biomarkers selected from the group consisting of
- (i) a first group consisting of AAT, Fibrinogen, Haptoglobin, C3, beta-2-macroglobulin, CRP, ICAM-1, TIMP-1, TNFR2, IL-18, IL-1RA, IL-6, IL-8, TNF-alpha, and VEGF (“Group I biomarker”), and/or
- (ii) a second group consisting of A2Macro, MMP-2, VCAM-1, IL-17, and SCF (“Group II biomarker”),
- wherein the binding partners are grouped together on a substrate based on biomarker specificity and groups are physically separated from each other on the substrate.
2 more elements
26-36. (canceled)
Dependencies are inferred from the claim text.